logo
CanyamAI summaries for academic research
language
MobileMobile
  • Phone FeatureWeChat Mini Program
EnglishEnglish
noticeNotice
BlogBlog
delete
arrow
Back
N

Nobuyuki Yamamoto

department of pediatrics

73H-index
1.1KPaper Count
2.9WCitation Count
Published Papers 236
Publication Date
logo
Spatial and graded heterogeneity of GD2 expression in neuroblastoma revealed by whole-slide immunohistochemistry
errCancer Immunology Immunotherapy
IF5.1
err2026-07-29
err0
errOAAI
errTomoko Fujikawa; Shotaro Inoue; Akihiro Nishimura; Naoko Nakatani; Nobuyuki Yamamoto; Toshiki Hyodo; Makiko Yoshida; Daiichiro Hasegawa; Kandai Nozu; Akihiro Tamura
errShare
errSave
Systematic review of antiemetic therapy for low emetogenic chemotherapy: comparing 5-HT3 receptor antagonists and dexamethasone
errInternational Journal of Clinical Oncology
IF2.8
err2026-07-21
err0
PREAI
errTakeshi Aoyama; Hirotoshi Iihara; Masakazu Abe; Makoto Wada; Keiko Iino; Tatsuo Akechi; Chiyo K. Imamura; Ayako Okuyama; Keiko Ozawa; Yong-Il Kim; Hidenori Sasaki; Eriko Satomi; Masayuki Takeda; Ryuhei Tanaka; Takako Eguchi Nakajima; Naoki Nakamura; Junichi Nishimura; Mayumi Noda; Kazumi Hayashi; Takahiro Higashi; Narikazu Boku; Koji Matsumoto; Yoko Matsumoto; Kenji Okita; Nobuyuki Yamamoto; Kenjiro Aogi
errShare
errSave
Development of a clinical prediction model using digital device data for interstitial lung disease in patients with unresectable stage III non-small cell lung cancer treated with durvalumab
errLung Cancer
IF4.4
err2026-05-25
err0
PREAI
errSatoshi Ikeda; Hirotsugu Kenmotsu; Ryo Koto; Takehiro Hirai; Mizue Ogi; Yoshinori Sato; Chikako Iwao; Hiroshi Kitagawa; Nobuyuki Yamamoto
errShare
errSave
Docetaxel plus ramucirumab immediately after immunotherapy in advanced NSCLC: A phase II study (DRUN)
errLung Cancer
IF4.4
err2026-05-12
err0
errOAAI
errYuhei Harutani; Hiroaki Akamatsu; Takeya Sugimoto; Toshiaki Takakura; Eri Takase; Takahiro Kaki; Katsuyuki Furuta; Ryota Shibaki; Keita Nakaguchi; Seigo Sasaki; Koichi Sato; Yuichi Ozawa; Yusuke Murakami; Atsushi Washioka; Kuninobu Kanai; Ke Wan; Toshio Shimokawa; Nobuyuki Yamamoto
errShare
errSave
Hydrogen Isotope Exchange in Pyridine Catalyzed by an Iron(II) Imido Complex: Counterion-Directed Regioselectivity
errAngewandte Chemie-International Edition
IF16.9
err2026-04-01
err0
errOAAI
errFeng, Bin; Li, Guorong; Gao, Yafei; Yamamoto, Nobuyuki; Pink, Maren; Peng, Qian; Smith, Jeremy M.
errShare
errSave
Phase Ia/Ib trial of the safety and efficacy of mobocertinib in combination with T-DM1 for patients with HER2-mutant solid tumors (WJOG16022M)
errEuropean Journal of Cancer
IF7.1
err2026-03-19
err0
errOAAI
errHiroaki Kanemura; Junko Tanizaki; Koji Matsumoto; Toshiki Masuishi; Taichi Isobe; Hirotsugu Kenmotsu; Yu Sunakawa; Toshio Shimizu; Yasutaka Chiba; Nobuyuki Yamamoto; Kazuhiko Nakagawa; Hidetoshi Hayashi
errShare
errSave
Real-world adherence to antiemetic guidelines in Japanese patients receiving high or carboplatin-based moderate emetic risk chemotherapy
errInternational Journal of Clinical Oncology
IF2.8
err2025-10-15
err0
PREAI
errAyako Okuyama; Takahiro Higashi; Masakazu Abe; Toshinobu Hayashi; Hirotoshi Iihara; Keiko Iino; Chihiro Ishii; Kenji Okita; Makoto Wada; Nobuyuki Yamamoto; Sadamoto Zenda; Kenjiro Aogi; Eriko Satomi
errShare
errSave
Radiotherapy-free pembrolizumab combined with chemotherapy for locally advanced non-small-cell lung cancer with PD-L1 tumour proportion score of 50% or higher (Evolution trial): a multicentre, single-arm, phase 2 study
errThe Lancet Oncology
IF0
err2025-10-11
err0
PREAI
errAkito Hata; Taira Ninomaru; Hideaki Okada; Yoshihito Kogure; Masahide Oki; Nobuyuki Katakami; Takashi Kijima; Toshihide Yokoyama; Hirotaka Matsumoto; Yuki Sato; Terufumi Kato; Shunichi Sugawara; Takeshi Sawada; Kenichi Yoshimura; Takashi Seto; Kazuhiko Nakagawa; Isamu Okamoto; Nobuyuki Yamamoto
errShare
errSave
Efficacy and safety of brigatinib after alectinib in patients with ALK-positive NSCLC: Integrated analysis of the ALTA-2 and J-ALTA studies
errLung Cancer
IF4.4
err2025-10-09
err0
PREAI
errTony Mok; Makoto Nishio; Tatsuya Yoshida; Myung-Ju Ahn; Kentarou Kudou; Takayuki Asato; Hui Yang; Xin Tong; Sylvie Vincent; Pingkuan Zhang; Nobuyuki Yamamoto; Edward S. Kim
errShare
errSave
Genetic analysis of cell-free DNA in follicular lymphoma in comparison with tissue-derived DNA
errLEUKEMIA & LYMPHOMA
IF2.2
err2025-10-01
err0
PREAI
errHori, Yoshikazu; Hosoi, Hiroki; Osuga, Mitsuo; Iwamoto, Ryuta; Maekawa, Fumiyo; Okamura, Tadashi; Murata, Shogo; Mushino, Toshiki; Osato, Motomi; Ohno, Hitoshi; Yamamoto, Nobuyuki; Murata, Shin-Ichi; Koh, Yasuhiro; Takashi, Sonoki
errShare
errSave
Biological impact of chemotherapy during treatment with EGFR tyrosine kinase inhibitors for non-small cell lung cancer positive for EGFR activating mutations
errLung Cancer
IF4.4
err2025-09-16
err0
errOAAI
errEiji Iwama; Kazuko Sakai; Taishi Harada; Shintaro Kanda; Shunichi Sugawara; Toshihide Yokoyama; Hirokazu Taniguchi; Kaoru Tanaka; Ryo Toyozawa; Kenichi Koyama; Yoshitaka Zenke; Gen Kida; Yasuhiko Nishioka; Hiroshi Yokouchi; Masayuki Hirose; Kazuto Nishio; Nobuyuki Yamamoto; Yuichiro Ohe; Isamu Okamoto
errShare
errSave
Long-Term Safety and Effectiveness of Durvalumab in Unresectable Stage III non-small cell lung cancer in Japan: A Multicenter Prospective Study (AYAME)
errJournal of Thoracic Oncology
IF20.8
err2025-08-18
err0
errOAAI
errHirotsugu Kenmotsu; Yoshinobu Saito; Kiichiro Ninomiya; Shinya Uematsu; Burak Akdemir; Ayako Fukui; Ryo Koto; Masakazu Fujiwara; Chikako Iwao; Hiroshi Kitagawa; Ichiro Yoshino; Akihiko Gemma; Tetsuya Mitsudomi; Nobuyuki Yamamoto
errShare
errSave
Durvalumab plus irinotecan + cisplatin for untreated extensive-stage small cell lung cancer: REBORN, phase II study (WJOG13520L)
errLung Cancer
IF4.4
err2025-06-29
err0
errOAAI
errMotoko Tachihara; Hiroyasu Shoda; Yuki Akazawa; Takayo Ota; Masahide Oki; Yuki Sato; Shunichi Sugawara; Satoshi Ikeda; Toshihide Yokoyama; Hiroyasu Kaneda; Shoichi Itoh; Akihiro Bessho; Nobuyuki Katakami; Satoshi Morita; Kazuhiko Nakagawa; Isamu Okamoto; Nobuyuki Yamamoto
errShare
errSave
Phase III study of ramucirumab plus docetaxel versus atezolizumab for previously treated PD-L1 low or negative advanced non-small-cell lung cancer: WJOG10317L study
errLung Cancer
IF4.4
err2025-06-23
err0
PREAI
errYoshitaka Zenke; Seiji Niho; Yukihiro Toi; Masafumi Yamaguchi; Satoshi Hara; Yuki Akazawa; Yukio Hosomi; Kimio Yonesaka; Hiroaki Akamatsu; Toshihide Yokoyama; Junko Tanizaki; Kiyonobu Ueno; Hiroshi Gyotoku; Toshihiro Misumi; Kazuhiko Nakagawa; Nobuyuki Yamamoto; Masahiro Tsuboi
errShare
errSave
Epidemiology and clinical course of large cell neuroendocrine carcinoma of the lung: The Japanese lung cancer registry study
errLUNG CANCER
IF4.4
err2025-06-01
err0
PREAI
errShirai, Yukina; Shukuya, Takehito; Asao, Tetsuhiko; Takahashi, Kazuhisa; Shintani, Yasushi; Sekine, Ikuo; Takayama, Koichi; Inoue, Akira; Okamoto, Isamu; Kawaguchi, Tomoya; Yamamoto, Nobuyuki; Miyaoka, Etsuo; Yoshino, Ichiro; Date, Hiroshi
errShare
errSave
Neoadjuvant Concurrent Chemo–Immuno–Radiation Therapy Followed by Surgery and Adjuvant Immunotherapy for Resectable Stage III N2 NSCLC: Primary Results From the SQUAT Trial (WJOG 12119L)
errJournal of Thoracic Oncology
IF20.8
err2025-04-09
err0
PREAI
errAkira Hamada; Junichi Soh; Akito Hata; Kiyoshi Nakamatsu; Mototsugu Shimokawa; Yasushi Yatabe; Jun Suzuki; Masahiro Tsuboi; Hidehito Horinouchi; Yuichi Sakairi; Masayuki Tanahashi; Shinichi Toyooka; Morihito Okada; Natusmi Matsuura; Hisayuki Shigematsu; Yasumasa Nishimura; Nobuyuki Yamamoto; Kazuhiko Nakagawa; Tetsuya Mitsudomi
errShare
errSave
Pembrolizumab and Pemetrexed for Older Patients With Nonsquamous NSCLC and Programmed Cell Death-Ligand 1 Tumor Proportion Scores of Less Than 50%
errJTO CLINICAL AND RESEARCH REPORTS
IF3.5
err2025-03-01
err0
errOAAI
errKogure, Yoshihito; Hashimoto, Hiroya; Daga, Haruko; Fukuda, Yasushi; Bessho, Akihiro; Yamada, Tadaaki; Toi, Yukihiro; Kimura, Tomoki; Yoshioka, Hiroshige; Azuma, Koichi; Furuya, Naoki; Fukui, Yasutaka; Saito, Akiko M.; Yamamoto, Nobuyuki; Saka, Hideo; Kondo, Masashi
errShare
errSave
First-line nivolumab plus platinum chemotherapy and bevacizumab for advanced nonsquamous non-small cell lung cancer: A 3-year follow-up of the phase 3 randomized TASUKI-52 trial
errLUNG CANCER
IF4.4
err2025-03-01
err0
PREAI
errLee, Ki Hyeong; Lee, Jong-Seok; Sugawara, Shunichi; Kang, Jin Hyoung; Kim, Hye Ryun; Inui, Naoki; Hida, Toyoaki; Yoshida, Tatsuya; Tanaka, Hiroshi; Yang, Cheng-Ta; Inoue, Takako; Nishio, Makoto; Ohe, Yuichiro; Tamura, Tomohide; Yamamoto, Nobuyuki; Yu, Chong-Jen; Akamatsu, Hiroaki; Takahashi, Shigeru
errShare
errSave
A Dinuclear Nickel Complex for Electrocatalytic Nitrite Reduction
errINORGANIC CHEMISTRY
IF4.7
err2025-03-01
err0
PREAI
errPartovi, Sheyda; Losovyj, Yaroslav; Yamamoto, Nobuyuki; Smith, Jeremy M.
errShare
errSave
Long-term outcome of chemoimmunotherapy for extensive-stage small-cell lung cancer according to key clinical trial eligibility: 3-year outcomes from a prospective cohort study
errLUNG CANCER
IF4.4
err2025-01-01
err0
PREAI
errSugisaka, Jun; Fujimoto, Daichi; Tamiya, Motohiro; Hata, Akito; Matsumoto, Hirotaka; Yokoyama, Toshihide; Taniguchi, Yoshihiko; Uchida, Junji; Sato, Yuki; Kijima, Takashi; Tanaka, Hisashi; Furuya, Naoki; Masuda, Takeshi; Sakata, Yoshihiko; Miyauchi, Eisaku; Saito, Go; Miura, Satoru; Yamaguchi, Teppei; Daga, Haruko; Sakata, Shinya; Yamamoto, Nobuyuki; Akamatsu, Hiroaki
errShare
errSave

Research Directions

No research directions
Co-authors
Cooperation Journals
T
Tasuku Honjo
H-index: 143 · Papers: 737
J
James Chih‐Hsin Yang
H-index: 141 · Papers: 1.2K
Y
Yi‐Long Wu
H-index: 135 · Papers: 2.2K
T
Tony Mok
H-index: 131 · Papers: 1.1K
G
Gregory J. Riely
H-index: 127 · Papers: 1.3K
View more